Pharmacogenetics of immunosuppressant drugs: A new aspect for individualized therapy

Table 1 Candidate single-nucleotide polymorphisms related to the pharmacodynamics pathways of calcineurin inhibitors with quality of evidence of existing data and level of recommendation[6]

Drugs	Gene	SNP	MAF	QOE	LOR
	PPIA	rs8177826, rs6850	G = 0.033, G = 0.384	C, D	3, 4
	PPP3CA	rs45441997, rs3804358rs	G = 0.268, G = 0.133	A, A	1, 1
	PPP3CB	rs376679	T = 0.066	A	1
	PPP3R1	rs3039851, rs1868402	NA, G = 0.301	B, A	2, 1
	CALM1	rs12885713	T = 0.400	A	1
	CALM3	rs150954567, rs3814843, rs3814843	NA, C = 0.358, C = 0.018	A, C, C	1, 3, 3
	IL2	rs2069762, rs2069763, rs6822844	G = 0.232, A = 0.400, T = 0.146	A, B, C	4, 1, 3

Level of recommendation: 1: Highly recommended candidate; 2: Recommended candidate; 3: Potential candidate; 4: Candidate to exclude. SNP: Single-nucleotide polymorphism; CNI: Calcineurin inhibitor; LOR: Level of recommendation; MAF: Minor allele frequency; NA: Not available; QOE : Quality of evidence.